LINX Reflux Management System
Torax Medical · Decision date Jan 16, 2026
What did the FDA decide?
FDA records P100049/S040 as a supplement to PMA P100049, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 16, 2026.
FDA approval order statement
replacement of microscope and micrometer to perform inspections of incoming components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jan 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P100049/S040
- Regulatory pathway
- PMA supplement
- Applicant
- Torax Medical
- Product code
- LEI
- Decision code
- OK30
- Decision date
- Jan 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, ANTI-GASTROESOPHAGEAL REFLUX.
- Applicant
- Torax Medical
- Product code
- LEI
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100049/S038 · Related supplement
LINX Reflux Management System
P100049/S040 received
Application receipt date recorded by FDA.
P100049/S041 · Related supplement
LINX Reflux Management System
P100049/S040 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P100049. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100049
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LINX Reflux Management SystemP100049/S038 | Torax Medical | PMA supplement | Oct 8, 2025 | FDA |
LINX Reflux Management SystemP100049/S041 | Torax Medical | PMA supplement | Jan 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LEI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Implantica CE Reflux , Ltd. | PMA approval | Aug 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Torax Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4545 Creek Rd., Cincinnati, OH, 45242
Sources and methodology
- Original FDA record: P100049/S040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
